UNSPSC 51281664: Ribostamycin sulfate

This classification denotes an aminoglycoside antibiotic C17H34N4O10.H2O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier QFN1QU7PEN, chemically known as o-2,6-diamino-2,6-dideoxy-.alpha.-d-glucopyranosyl-(1->4)-o-(.beta-d-ribofuranosyl-(1->5))-2-deoxy-d-streptamine sulfate, but more generally known as ribostamycin sulfate, which bears US NIH Compound Identifier 5702279. European Medicines Agency schedules in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04244MIG.

UNSPSC 51281664 Ribostamycin sulfate is a Commodity code that nominally describes a specific aminoglycoside antibiotic; however, the recent state and local opportunities tagged under this code do not reflect procurement of ribostamycin sulfate itself. Instead, the code shows activity related to pharmaceutical procurement more broadly, including antibiotic tablets and naloxone products, suggesting either misclassification in the tagging process or use of this code as a catch-all for pharmaceutical commodity orders. The opportunities demonstrate state and local health departments and county agencies acquiring finished pharmaceutical products and medical supplies through piggyback contracts and competitive bidding processes. Issuing bodies include state health departments and county community health agencies, with work involving warehouse-based pharmaceutical distribution and quarterly delivery of health-support supplies to public health facilities.

Recent opportunities span Illinois and Florida, with the Illinois Department of Public Health awarding a $2,999,999.11 piggyback pharmaceutical warehouse contract to Chartwell Rx LLC through the MMCAP Infuse consortium on August 28, 2026 for Doxycycline Hyclate 100mg and Ciprofloxacin Hydrochloride 500mg tablets (completed award, not open solicitation), and Seminole County, Florida posting an IFB on June 30, 2026 seeking 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually with a response deadline of July 26, 2026. Both opportunities involved fixed-term contracts with renewal options and required vendors to manage shipping and delivery logistics. The mismatch between the code's nominal scope and the actual pharmaceutical products being procured suggests this code may not be reliably tracked for ribostamycin sulfate purchasing specifically, limiting its usefulness for tracking genuine demand for that particular product.